Your World of Legal Intelligence
 United Kingdom | +44 (0) 20 7284 8080

Axsome Therapeutics Closes US Acquisition of Daytime Sleepiness Treatment Sunosi.

Document Cited in Related
Vincent

MANews-(C)2009-2022

US-based biopharmaceutical company Axsome Therapeutics, Inc. (NASDAQ: AXSM) has its US acquisition of Sunosi (solriamfetol) from Jazz Pharmaceuticals (NASDAQ: JAZZ), the company said.

Sunosi is a dual-acting dopamine and norepinephrine reuptake inhibitor indicated to improve wakefulness in adult patients with excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea.

The ex-US transaction is expected to close within 60 days.

Sunosi was approved by the US Food and Drug Administration in 2019 and by the European Medicines Agency in 2020 based on data from randomized placebo-controlled studies in patients with EDS associated with narcolepsy or OSA that demonstrated the superiority of Sunosi relative to placebo.

Sunosi should not be used in patients who are taking, or have stopped taking within the past 14 days, a medicine used to treat depression called a monoamine oxidase inhibitor.

The most common adverse reactions (incidence â[per mille][yen sign]5% and higher than placebo) reported in both the narcolepsy and OSA study populations were headache, nausea, decreased appetite, and anxiety.

Sunosi was evaluated in more than 900 adults with EDS associated with narcolepsy or OSA and was shown to maintain its effect relative to placebo...

To continue reading

Request your trial
COPYRIGHT Normans Media Ltd.

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT